Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   42732   clinical trials with a EudraCT protocol, of which   7035   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .

    Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the Clinical Trial Information System  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2019-002001-21
    Sponsor's Protocol Code Number:3597
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2021-06-08
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2019-002001-21
    A.3Full title of the trial
    BETTER-B: BETter TreatmEnts for Refractory Breathlessness. An International, Multicentre, Randomised Controlled Pragmatic Trial of Mirtazapine to alleviate Breathlessness in Palliative and End of Life Care.
    Studio internazionale, multicentrico, controllato, randomizzato per valutare l'utilizzo di Mirtazapina per alleviare la dispnea in cure palliative e nel trattamento di fine vita
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    BETTER-B: Better Treatments for Refractory Breathlessness.
    BETTER-B: un trattamento migliore per la difficoltà respiratoria
    A.3.2Name or abbreviated title of the trial where available
    BETTER-B
    BETTER-B
    A.4.1Sponsor's protocol code number3597
    A.5.1ISRCTN (International Standard Randomised Controlled Trial) NumberISRCTN10487976
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorUniversity College Dublin
    B.1.3.4CountryIreland
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportEuropean Union Horizon 2020 research and innovation programme
    B.4.2CountryBelgium
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationUniversity College Dublin
    B.5.2Functional name of contact pointRabia Hussain
    B.5.3 Address:
    B.5.3.1Street AddressUCD School of Medicine
    B.5.3.2Town/ cityBelfield
    B.5.3.3Post codeDublin 4
    B.5.3.4CountryIreland
    B.5.4Telephone number0035317164593
    B.5.6E-mailrabia.hussain@ucd.ie
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Mirtazapine
    D.2.1.1.2Name of the Marketing Authorisation holderKRKA Sverige AB
    D.2.1.2Country which granted the Marketing AuthorisationDenmark
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameMirtazapine KRKA 15mg Film-Coated Tablets
    D.3.2Product code [37185]
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNMIRTAZAPINA
    D.3.9.1CAS number 61337-67-5
    D.3.9.2Current sponsor codeNA
    D.3.9.4EV Substance CodeAS1
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typerange
    D.3.10.3Concentration number15 to 45
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Refractory breathlessness in patients diagnosed with chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD).
    La dispnea refrattaria/cronica in pazienti affetti da broncopneumopatia cronica ostruttiva (BPCO) e malattia polmonare interstiziale (ILD).
    E.1.1.1Medical condition in easily understood language
    Breathlessness that continues despite optimal management of the underlying causes and current symptom relief measures, in patients suffering from lung disease.
    Dispnea persistente nonostante trattamento ottimale delle cause e dei sintomi in pazienti affetti da patologie polmonari
    E.1.1.2Therapeutic area Diseases [C] - Respiratory Tract Diseases [C08]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level LLT
    E.1.2Classification code 10009032
    E.1.2Term Chronic obstructive lung disease
    E.1.2System Organ Class 100000004855
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To determine whether mirtazapine is an effective treatment for the reduction of self-reported worst breathlessness over the past 24 hours measured at day 56 post start of treatment compared to placebo in patients with COPD (Chronic Obstructive Pulmonary Disease) or ILD (Interstitial Lung Disease) in palliative and end of life care.
    Determinare se la Mirtazapina è un trattamento efficace per la riduzione della peggiore dispnea auto-riportata (misurata attraverso la scala numerica NRS a 56 giorni dall’inizio del trattamento con Mirtazapina o placebo) in pazienti con dispnea cronica o refrattaria confrontandola con la peggiore dispnea riportata alla visita basale
    E.2.2Secondary objectives of the trial
    - To assess the effectiveness of mirtazapine, compared to placebo, over time at days 7,14, 28, 56 & 180
    - To evaluate safety, toxicity and tolerability of mirtazapine
    - To identify which patient characteristics are most associated with benefit from mirtazapine, specifically assessing the impact of age: gender; functional status; aetiology; and baseline intensity of: breathlessness and its characteristics; anxiety; depression; and concomitant opioid administration
    - To assess the cost-effectiveness of mirtazapine treatment from a societal perspective (i.e. including formal and informal care received), when compared with best standard care
    - To demonstrate the feasibility of delivering mirtazapine treatment across the different European countries in terms of acceptability of the offered treatment and compliance with treatment
    - To evaluate the impact of patients receiving mirtazapine on caregivers, in particular primary caregiver reports of their time in hours, burdens and experiences
    - valutare l'efficacia della mirtazapina, rispetto al placebo, ai giorni 7,14, 28, 56 e 180
    - valutare sicurezza, tossicità e tollerabilità della mirtazapina
    - Identificare le caratteristiche principali del paziente associate al beneficio della mirtazapina, in particolare l'impatto dell'età: sesso; stato funzionale; eziologia; e intensità di base di: dispnea e sue caratteristiche; ansia; depressione; e somministrazione concomitante di oppioidi
    - Valutare il rapporto costo-efficacia del trattamento con mirtazapina in una prospettiva sociale ( compresa l'assistenza formale e informale ricevuta), rispetto alle migliori cure standard
    - Dimostrare la fattibilità del trattamento nei diversi paesi europei in termini di accettabilità del trattamento offerto rispetto al trattamento standard
    -
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives

    Life quality
    Version: 7.0
    Date: 23/10/2020
    Title: The BETTER-B sub-study is the Caregiver sub-study.
    Objectives: The aim of this sub study is to assess the caregiver burden and the experience of the participants caregivers and close family members.

    Qualita' della vita
    Versione: 7.0
    Data: 23/10/2020
    Titolo: BETTER-B - qualità della vita del Caregiver.
    Obiettivi: Lo scopo di questo studio secondario è valutare il carico del caregiver e l'esperienza dei partecipanti che si prendono cura di loro e dei familiari stretti.
    E.3Principal inclusion criteria
    1.Aged = 18 years old
    2.Diagnosed with:
    •Chronic obstructive pulmonary disease (COPD), or
    •Interstitial lung disease (ILD) including chronic fibrotic lung disease following SARS-CoV-2 infection
    3.Breathlessness severity: Modified MRC breathlessness scale of:
    •grade 3 (I stop for breath after walking about 100 yards or after a few minutes on level ground) or
    •Grade 4 (I am too breathless to leave the house or I am breathless when dressing or undressing)
    4.On optimal treatment of the underlying condition in the opinion of the identifying clinician
    5.Management of the underlying condition unchanged for the previous 2 weeks
    6.Reversible causes of breathlessness optimally treated in the opinion of the identifying clinician
    7.If female, must be (as documented in patient notes):
    a)postmenopausal (no menses for 12 months without an alternative medical cause), or
    b)surgically sterile (hysterectomy, bilateral salpingectomy or bilateral oophorectomy), or
    c)using acceptable contraception (which must be continued for 7 days after the last dose of IMP)
    8.Able to complete questionnaires and trial assessments
    9.Able to provide written informed consent

    Caregiver eligibility:
    Caregivers will be identified by an included patient participant as the
    person closest to them, providing the patient participant is willing for
    them to be approached.

    Caregivers must meet all of the following criteria to be eligible:
    1.Identified by an included patient as the person closest to them
    2.Aged =18 years old
    3.Able to complete questionnaires and assessments
    4.Able to provide written informed consent
    1. Età > 18 anni
    2. Diagnosi di:
    • Malattia polmonare cronica ostruttiva (BPCO) e / o
    • Malattia polmonare interstiziale (ILD), inclusa la malattia polmonare fibrotica cronica post SARS-CoV-2
    3. Severità della dispnea valutata secondo scala MRC modificata (nMRC)
    • Grado 3 (Mi fermo per respirare dopo aver camminato per circa 90 metri dopo alcuni minuti su una superficie
    piana
    o
    • Grado 4 (Sono senza fiato per uscire di casa e, mi manca il fiato quando mi vesto e mi spoglio)
    4. Giudizio clinico idoneo al trattamento (consultare sezione Errore. L'origine riferimento non è stata trovata. del protocollo)
    5. Condizione clinica invariata nelle ultime 2 settimane
    6. Cause reversibili di affanno sono state trattate nel miglior modo, secondo l'opinione del clinico che ha in cario il paziente
    7. Se il pazinete è di sesso femminile , deve essere (come documentato nel
    foglio informativo per il paziente):
    a) in fase post menopausa (intesa come assenza del ciclo mestuale da almeno 12 mesi) o
    8. b) sterilità chirurgica (isterectomia, salpingectomia bilaterale o ooforectomia bilaterale), o
    c) uso di contraccetivi (che deve essere continuato fino a 7 giorni dopo l’ultima dose di IMP assunta)
    8. abile a completare i questionari e le visite di studio
    9. in grado di fornire consenso informato scritto
    E.4Principal exclusion criteria
    1.Existing antidepressant use, or other serotonergic active substances
    (e.g. linezolid, St John's wort)
    2.Known contraindication to mirtazapine
    3.Hypersensitivity to the active substance or to any of the components of
    mirtazapine or placebo (e.g. lactose intolerance)
    4.Australia modified Karnofsky Performance Scale =40
    5.Pregnant or breast-feeding women. For women of childbearing
    potential (those not post-menopausal or surgically sterile) this must be
    confirmed by a pregnancy test (urine) within 7 days prior to
    randomisation
    6.Patients with known cardiovascular disease or acute cardiac events
    within 3 months prior to randomisation (e.g. myocardial infarction,
    unstable angina pectoris, or significant cardiac conduction disturbance)
    7.Patients with jaundice or known hepatic impairment in the opinion of
    the identifying clinician (e.g. bilirubin >25micromol/L, and AST and ALT
    >2 times upper limit of normal)
    8.Patients with known renal impairment in the opinion of the identifying
    clinician (e.g. creatinine >132micromol/L and eGFR
    <30mL/min/1.73m2)
    9.Patients with uncontrolled blood pressure in the opinion of the
    identifying clinician
    10.Patients with uncontrolled diabetes mellitus in the opinion of the
    identifying clinician
    11.Patients with uncontrolled seizures, epilepsy or organic brain
    syndrome in the opinion of the identifying clinician
    12.Patients with severe depression or suicidal thoughts in the opinion of
    the identifying clinician
    13.Patients with a history of psychotic illness (schizophrenia, or other
    psychotic disturbances) in the opinion of the identifying clinician
    14.Patients with bipolar disorder, or a history of mania or hypomania in
    the opinion of the identifying clinician
    15.Patients currently enrolled in another interventional trial
    16.Patients with known congenital QT prolongation or family history for
    QT prolongation
    17.Use of medicines that cause QT prolongation such as macrolides and
    typical antipsychotics (unless required in low-dose to relieve nausea,
    e.g. haloperidol =5mg/24h, levomepromazine =25mg/24h)
    18.Patients with a known history of suicide-related events
    1. Uso di antidepressivi o altri principi attivi serotoninergici (ad es. Linezolid,
    iperico)
    2. Nota controindicazione all’utilizzo di Mirtazapina
    3. Ipersensibilità al principio attivo o ad uno qualsiasi dei componenti di Mirtazapina o placebo (ad es. Intolleranza al lattosio)
    4. Australia modified Karnofsky Performance Scale =40
    5. Donne in gravidanza o in allattamento. Per le donne in età fertile (non post-menopausa o chirurgicamente sterili) lo stato di NON gravidanza deve essere confermato da un test di gravidanza (urine) eseguito non
    oltre I 7 giorni dalla randomizzazione
    6. Pazienti che hanno avuto eventi cardiaci acuti entro 3 mesi prima dalla randomizzazione (infarto del miocardio, angina pectoris instabile o disturbo significativo della conduzione cardiaca) possono essere arruolati
    a secondo del giudizio del clinico che ha in carico il pz
    7. Pazienti con ittero o compromissione epatica possono essere arruolati a seconda del giudizio del clinic che ha in carico il paziente
    8. Pazienti con insufficienza renale nota possono essere arruolati a seconda del giudizio del clinic che ha in carico il paziente
    9. Pazienti con ipertensione incontrollata possono essere arruolati a seconda del giudizio del clinic che ha in carico il paziente
    10.Pazienti con diabete mellito incontrollato possono essere arruolati a seconda del giudizio del clinic che ha in carico il paziente
    11.Pazienti con convulsioni incontrollate, epilessia o sindrome cerebrale possono essere arruolati a seconda del giudizio del clinic che ha in carico il paziente
    12.Pazienti con grave depressione o pensieri suicidi possono essere arruolati a seconda del giudizio del clinic che ha in carico il paziente
    13.Pazienti con storia di malattia psichiatrica (schizzofrenia, o altri disturbi psichiatrici) possono essere arruolati a seconda del giudizio del clinico che ha in carico il paziente
    14.Pazienti con disturbi bipolari, o con storia di mania o ipomania possono essere arruolati a giudizio del clinic che ha in carico il paziente
    15.Pazienti attualmente arruolati in altri studi interventistici
    16.Pazienti con prolungamento dell’intervallo QT congenito o con familiarità di prolungamento dell’intervallo QT
    17. Uso di medicinali che causano prolungamento dell'intervallo QT come macrolidi e antipsicotici tipici (a meno che non sia richiesto a basse dosi per alleviare la nausea, ad es. Aloperidolo =5 mg / 24 ore,
    levomepromazina =25 mg / 24 ore)
    18. Pazienti con precedenti eventi associati a tentativi di suicidio
    E.5 End points
    E.5.1Primary end point(s)
    The primary objective is to determine whether mirtazapine is an effective treatment for the reduction of self-reported worst breathlessness over the past 24 hours measured at day 56 post start of treatment compared to placebo in patients with COPD or ILD in palliative and end of life care. The primary endpoint is worst breathlessness over the last 24 hours at day 56 post start of treatment as assessed by numerical rating scale (NRS, 0=no breathlessness to 10=worst possible breathlessness). Day 56 post start of treatment was chosen to allow sufficient time for the intervention to have an effect, it is a timescale which will be useful in palliative and end of life care and we can collect the primary outcome without too much attrition.
    L'obiettivo primario è determinare se la mirtazapina è un trattamento efficace per la riduzione della peggiore dispnea auto-segnalata nelle ultime 24 ore misurata al giorno 56 dopo l'inizio del trattamento rispetto al placebo nei pazienti con BPCO o ILD in cure palliative e di fine vita . L'endpoint primario è la peggiore dispnea nelle ultime 24 ore al giorno 56 dopo l'inizio del trattamento, come valutato dalla scala di valutazione numerica (NRS, da 0 = assenza di respiro a 10 = peggior dispnea possibile). Il giorno 56 dopo l'inizio del trattamento è stato scelto per consentire un tempo sufficiente affinché l'intervento abbia un effetto, è un lasso di tempo che sarà utile nelle cure palliative e di fine vita e possiamo raccogliere l'esito primario senza troppi attriti.
    E.5.1.1Timepoint(s) of evaluation of this end point
    The primary outcome will be evaluated when participants have reached day 56 post start of treatment.
    L'outcome primario sarà valutato al giorno 56 dopo l'inizio del trattamento.
    E.5.2Secondary end point(s)
    •Worst & average breathlessness over the last 24 hours as assessed by NRS at days 7, 14, 28 and 180 post start of treatment
    •Number & duration of episodes of breathlessness over the last 24 hours
    •Physical & emotional aspects of breathlessness as assessed by the Chronic Respiratory Questionnaire (CRQ) at days 14, 28, 56 and 180 post start of treatment
    •Physical symptoms as assessed by the IPOS at days 14, 28, 56 and 180 post start of treatment
    •QoL as assessed by the EQ-5D-5L and associated VAS at days 14, 28, 56, 180 post start of treatment and AKPS at days 14, 28, 56 and 180
    •Anxiety & depression as assessed by the Hospital Anxiety and Depression Scale (HADS) at days 28, 56 and 180
    •Perceived self-efficacy as measured by the Generalized Self-Efficacy Scale (GSES) at day 56 post start of treatment
    • Opioid medication usage at days 7, 14, 28, 56 and 180
    •Healthcare services received within 28 and 56 days post start of treatment and in the 3 month period prior to day 180 post start of treatment as measured by the Client Services Receipt Inventory
    (CSRI)
    •Safety as assessed by the occurrence of:
    oSAEs, SARs and SUSARs at days 7, 14, 28 and 56 post start of treatment
    oDeaths by day 56 and day 180 post start of treatment
    •Toxicity as assessed by adverse reactions (ARs) coded according to mild, moderate or severe as reported at days 7, 14, 28 and 56 post start of treatment
    •Tolerability as assessed by the proportion of patients not withdrawing due to adverse reactions
    •Baseline demographics & characteristics will be measured to enable prognostic evaluation of those factors most associated with benefit from mirtazapine (benefit as measured by worst breathlessness over the last 24 hours at day 56 post start of treatment. Specifically assessing:
    oage
    ogender
    ofunctional status, aetiology
    obaseline intensity of breathlessness
    oanxiety and depression (as measured by HADS)
    oconcomitant opioid administration
    •Formal and informal care use over the previous period as measured by the CSRI at days 28, 56 and 180 post start of treatment, to examine hours of care and (using country specific unit costs) costs of services
    •Acceptability of the offered treatment as assessed by the recruitment conversion rate, the number of people withdrawing from treatment, and the number of participants who request mirtazapine from their
    doctor/clinician after 56 days post start of treatment
    •Treatment compliance as measured by the:
    oproportion and type of dropouts over 56 days post start of treatment,
    oproportion of tablets taken over 56 days post start of treatment,
    oproportion of participants who escalate dose at days 14 and 28 post
    start of treatment
    oOff trial treatment compliance to 180 days post start of treatment
    •Caregiver's perceived impact on the participant and themselves as measured by:
    oWorst & average rating of the participant's breathlessness over the last 24 hours as assessed by NRS (0=no breathlessness to 10=worst possible breathlessness) at days 28, 56 and 180 post start of treatment
    oCaregiver assessment of the participant's number and duration of episodes of breathlessness over the last 24 hours
    oInformal care hours as measured by the CSRI at days 28, 56 and 180 post start of treatment
    oCaregiver self-reported burden as measured by the Zarit Burden interview at days 28, 56 and 180 post start of treatment
    oCaregiver self-reported experiences of caregiving as measured by the Positive Aspects of Caregiving scale at days 28, 56 and 180 post start of treatment;
    oCaregiver perspectives on participants' situation as measured by the
    Integrated Palliative care outcome scale at days 28, 56 and 180 post start of treatment
    oCaregiver overall health and wellbeing as measured by EQ-5D-5L and associated VAS at days 28, 56 and 180 post start of treatment
    oCaregiver perspectives on how participants would rate their own overall health & wellbeing as measured by the proxy EQ-5D-5L & associated VAS at days 28, 56 and 180 post start of treatment
    Valutare l’efficacia della Mirtazapina rispetto al placebo ai giorni 7,14,28,56 e 180 dall’inizio del trattamento, valutando:
    o La peggiore dispnea e la dispnea media nelle ultime 24h Misurata con la scala NRS riportata dal paziente:
    o Altri sintomi fisici (misurati dal questionario CRQ e IPOS completato dal paziente) e della qualità della vita complessiva (misurati da AKPS e EQ-5D-5L completati dal paziente completato dal paziente e dal caregiver (solo al giorno 28, 56 180);
    o Ansia, depressione (misurata da HADS) e senso di autoefficacia percepita (misurata da GSES)
    o Il consumo di oppioidi
    o Accessi in ospedale, in particolare accessi non programmati (accessi in PS con co senza ricovero) rilevati dal questionario CSRI.
    • Valutazione della safety, della tossicità e della tollerabilità della Mirtazapina.
    • Identificare quali caratteristiche del paziente sono maggiormente associate ai benefici della Mirtazapina, valutando specificamente l'impatto dell'età: sesso; stato funzionale; eziologia; e intensità di base di: mancanza di respiro e le sue caratteristiche; ansia; depressione; e concomitante somministrazione di oppioidi.
    • Valutare il rapporto costo-efficacia del trattamento con Mirtazapina dal punto di vista sociale (ovvero includendo le cure formali e informali ricevute), rispetto alle migliori cure standard.
    • Dimostrare la fattibilità del trattamento con Mirtazapina nei diversi paesi europei in termini di accettabilità del trattamento offerto rispetto al trattamento standard dei diversi paesi coinvolti.
    • Valutare l'impatto dei pazienti che ricevono Mirtazapina sui caregiver, in particolare le relazioni del caregiver primario (famiglia o amico) sui loro oneri,sulla qualità della vita e sull'esperienza di caregiving e sulle ore totali di cure informali.
    E.5.2.1Timepoint(s) of evaluation of this end point
    All secondary endpoint will de evaluated when all participants have been followed up to completion i.e. 180 days post randomisation.
    Tutti gli endpoint secondari saranno valutati al termine dell'intervento, ovvero 180 giorni dopo la randomizzazione.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety No
    E.6.5Efficacy No
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA8
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Germany
    Ireland
    Italy
    Poland
    United Kingdom
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of trial is defined as the date of the final data download for final analysis.
    La fine della sperimentazione è definita come la data del download finale dei dati per l'analisi statistica.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months7
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months6
    E.8.9.2In all countries concerned by the trial days1
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 162
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 162
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state90
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 219
    F.4.2.2In the whole clinical trial 324
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    If participants believe they have had a benefit from the trial treatment, they may wish to take mirtazapine off-trial. Participants are advised that they may approach their GPs following trial completion for off-trial prescribing of mirtazapine.
    The trial stipulates that participants should have dose tapered back to 15mg or completed dose tapering before approaching their GP for a prescription.
    Se i partecipanti ritengono di aver ottenuto un beneficio dal trattamento possono desiderare di continuare la mirtazapina al di fuori dello studio.

    I partecipanti sono informati che possono contattare il medico di medicina generale alla fine dello studio per ottenere la prescrizione del farmaco.

    Lo studio prevede che i partecipanti riducano la dose a 15 mg o che abbiano completato la riduzione della dose, come da protocollo, prima di contattare il medico curante per la prescrizione.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-05-07
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2020-12-01
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2022 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA